Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
abandoned, aforementioned, Alfimeprase, aliquoting, arm, assumption, attaining, attention, beta, BioOncology, BioPharma, bioreactor, bought, boyer, branded, Cabilly, CAMPATH, CAP, certiorari, chargeback, charitable, choose, CHOP, CIP, Citigroup, Clark, clearing, CMS, comment, comparison, compelling, compendium, contest, contrast, correspondingly, count, coupon, CRC, cyclophosphamide, debra, dedicate, destroyed, DI, diligently, discharge, divert, donated, double, doxorubicin, DSMB, duly, education, emerging, empirical, employment, Escrow, ESP, excellent, exhibit, exploit, extinguish, extinguished, flat, flexibility, furnished, gastrointestinal, gefitinib, gestational, Goldman, Google, grand, heading, herbert, hereof, herewith, holder, Humatrope, Humira, Huningue, hypersensitivity, hypertonic, Ian, inapplicable, incorrect, Indenture, induction, inexpensive, Instruction, intravitreal, ISS, Johnson, Kingdom, lapatinib, lawfully, leasehold, lengthier, leukotriene, liable, lot, Maine, malate, myeloma, neovascular, Nexavar, nontransferable, notification, Nuvelo, occupancy, Oceanside, omitted, owner, panitumumab, path, PDL, peer, Pfizer, Pharmacopeia, placement, postretirement, power, Prader, procedure, proforma, promulgated, qualification, qui, ratifying, ratio, RCC, recommendation, redacted, reed, reexamination, rejecting, Remicade, reorder, resale, resubstitution, retaliatory, retinal, Rocheexercised, rolling, routine, Saizen, saline, seal, SGA, shell, shortly, signature, smaller, sorafenib, statute, stead, steadily, step, sterility, stromal, submission, sunitinib, suspended, Sutent, tam, Teva, thereunto, therewith, Toll, Treasury, true, trustee, unchanged, undersigned, understood, unplanned, unresectable, unsealed, uptake, USP, valuable, VELCADE, Version, virtue, vulnerability, wait, waiting, wholly, Willi, writ, XELOX, ZactimaTM, Zyflo
Removed:
Academy, accelerated, accretion, acid, Advancement, aimed, alternatively, America, American, amino, ancillary, antidilutive, began, Biochemistry, Bulletin, capability, classification, commonly, community, compensated, conflict, consecutive, constitute, construing, contingent, convenience, cooperative, customized, defendant, dissemination, editorial, ending, endocrine, enhanced, entry, etanercept, existence, failed, Fellow, Finally, financed, fluctuate, foregoing, forma, formed, handling, idle, idling, impacted, improved, improving, inadequacy, indemnification, inflammatory, infringe, initiating, instituted, insufficient, invalidity, jointly, Jr, Lavigne, lessee, loan, low, MabThera, Markman, matured, Medicinal, medicine, methionine, Microbiology, modest, narrower, North, Northeast, panel, paper, park, Pennwalt, performed, pivotal, plaintiff, positively, Postdoctoral, predecessor, Princeton, pro, ProLease, Protecting, published, quantifiable, quantitative, randomized, rationale, recording, remote, representative, ruled, Sacramento, shareholder, shipping, showed, shown, size, slightly, slower, Society, sooner, SPC, sponsored, stay, staying, stipulation, strength, structure, subsumed, suit, supplement, supported, survival, targeted, Taxol, technical, technologically, temporary, treated, treating, trend, unanimously, unrelated, vascular
Filing tables
Filing exhibits
- 10-K Annual report
- 3.5 Bylaws
- 10.23 First Amendment to Transition Agreement Between Genentech, Inc. and Myrtle S. Potter Dated December 29, 2005
- 10.28 First Amendment to the Manufacturing and Supply Agreement Between Genentech, Inc. and Lonza Biologics, Inc. Dated March 14, 2005
- 10.30 First Amendment to the Toll Manufacturing Agreement by and Between Wyeth, Acting Through Its Wyeth Pharmaceuticals Division, and Genentech, Inc. Dated December 8, 2004
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Genentech similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1) | Registration Statement (Form S-3 No. 333-37072) of Genentech, Inc., |
2) | Registration Statement (Form S-8 No. 333-115219) pertaining to the 1999 Stock Plan, 1991 Employee Stock Plan, and 2004 Equity Incentive Plan of Genentech, Inc., |
3) | Registration Statement (Form S-8 No. 333-87444) pertaining to the 1999 Stock Plan of Genentech, Inc., |
4) | Registration Statement (Form S-8 No. 333-94749) pertaining to the Tax Reduction Investment Plan of Genentech, Inc., |
5) | Registration Statement (Form S-8 No. 333-90669) pertaining to the 1999 Stock Plan and 1991 Employee Stock Plan of Genentech, Inc., |
6) | Registration Statement (Form S-8 No. 333-83989) pertaining to the 1999 Stock Plan and 1991 Employee Stock Plan of Genentech, Inc., and |
7) | Registration Statement (Form S-8 No. 333-83157) pertaining to the 1990 Stock Option/Stock Incentive Plan, 1994 Stock Option Plan, and 1996 Stock Option/Stock Incentive Plan of Genentech, Inc.; |
of our reports dated February 10, 2006, with respect to the consolidated financial statements and schedule of Genentech, Inc., Genentech, Inc. management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Genentech, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2005.
/s/ ERNST & YOUNG LLP |
Palo Alto, California
February 10, 2006